Your Health, We Care
Concomitant use with a PPI decreases dacomitinib concentrations, which may reduce Dacomitinib efficacy. Avoid the concomitant use of PPIs with Dacomitinib. As an alternative to PPIs, use locally-acting antacids or an H2-receptor antagonist. Administer Dacomitinib at least 6 hours before or 10 hours after taking an H2-receptor antagonist.
Concomitant use of Dacomitinib increases the concentration of drugs that are CYP2D6 substrates, which may increase the risk of toxicities of these drugs. Avoid concomitant use of Dacomitinib with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities.
from FDA，2020.12
